Palo Alto, Calif. – Cooley advised Guardant Health on the closing of its $100 million Series D financing, which included equity financing and a term loan facility. The round was led by OrbiMed and also included existing investors Khosla Ventures, Sequoia Capital, Lightspeed Venture Partners, Pejman Mar, Formation 8 and Heritage Group.
According to Guardant Health, the funding will help expand the technical and commercial lead of Guardant360 – the world's first comprehensive, non-invasive genomic sequencing test for cancer.
The team advising Guardant Health included Mark Weeks, Josh Seidenfeld, Eric Batill, Matt Fleming, Mischi a Marca, Amanda Fant, Maricel Mojares-Moore, Aaron Pomeroy and Jonathan Rivinus.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.